The prevention opportunities of retinopathy in diabetic patients – position paper endorsed by the Polish Lipid Association
Cardiovascular diseases (CVD) prevention does not only mean effective fight against the existing and well-recognized cardiovascular risk factors, but also against their complications, including micro- and macrovascular complications. Only then we might comprehensively reduce CVD burden and cardiovas...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2024-12-01
|
| Series: | Archives of Medical Science |
| Subjects: | |
| Online Access: | https://www.archivesofmedicalscience.com/The-prevention-opportunities-of-retinopathy-in-diabetic-patients-position-paper-endorsed,197331,0,2.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832584775410384896 |
|---|---|
| author | Maciej Banach Stanisław Surma Grzegorz Dzida Jacek Jóźwiak Bogusław Okopień Jacek Rysz Konrad Szosland Andrzej Grzybowski |
| author_facet | Maciej Banach Stanisław Surma Grzegorz Dzida Jacek Jóźwiak Bogusław Okopień Jacek Rysz Konrad Szosland Andrzej Grzybowski |
| author_sort | Maciej Banach |
| collection | DOAJ |
| description | Cardiovascular diseases (CVD) prevention does not only mean effective fight against the existing and well-recognized cardiovascular risk factors, but also against their complications, including micro- and macrovascular complications. Only then we might comprehensively reduce CVD burden and cardiovascular and cause-specific morbidity and mortality. In relation to obesity, prediabetes and especially diabetes, we recognize a number of potential dangerous non-cardiovascular complications, such as neuropathy, nephropathy and retinopathy. The latter’s prevalence is even 30–40% and may appear in as many as 15% of patients with prediabetes. If not treated well it might result in the need for eye surgery or even vision loss. Fenofibrate has had a long history of evidence suggesting its preventive role in primary and especially secondary prevention of retinopathy, what has been investigated since the FIELD trial 19 years ago. Thus, given the obesity (the prevalence of 30% in Poland) and diabetes (10% which is predicted to be doubled in next 25 years) epidemic, we should look for the effective methods not only to optimize fasting blood glucose and haemoglobin A1C, but also atherogenic dyslipidaemia and their complications, including retinopathy. In this Position Paper by the Polish Lipid Association (PoLA) we have reviewed the current stage of knowledge on possible mechanisms by which fenofibrate may contribute to retinopathy prevention, available data on safety and efficacy, to finally recommend administering fenofibrate in prevention of this dangerous diabetic complication, which significantly affects quality of life and disability-adjusted life-years (DALY). This intervention – well-recognized and already in common use in diabetic patients – may significantly improve population health in Poland and worldwide. |
| format | Article |
| id | doaj-art-219f8708cd734ed7a89c276364485ccb |
| institution | Kabale University |
| issn | 1734-1922 1896-9151 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| series | Archives of Medical Science |
| spelling | doaj-art-219f8708cd734ed7a89c276364485ccb2025-01-27T10:45:12ZengTermedia Publishing HouseArchives of Medical Science1734-19221896-91512024-12-012061754176910.5114/aoms/197331197331The prevention opportunities of retinopathy in diabetic patients – position paper endorsed by the Polish Lipid AssociationMaciej Banach0https://orcid.org/0000-0001-6690-6874Stanisław Surma1https://orcid.org/0000-0001-8073-6664Grzegorz Dzida2https://orcid.org/0000-0002-9742-1797Jacek Jóźwiak3https://orcid.org/0000-0002-2645-7274Bogusław Okopień4https://orcid.org/0000-0001-7228-2906Jacek Rysz5https://orcid.org/0000-0002-2757-6443Konrad Szosland6https://orcid.org/0000-0002-7186-9243Andrzej Grzybowski7https://orcid.org/0000-0002-3724-2391Center for the Atherosclerosis and Cardiovascular Diseases Prevention, Faculty of Medicine, the John Paul II Catholic University of Lublin (KUL), Lublin, PolandDepartment of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, PolandDepartment of Internal Medicine, Medical University of Lublin, Lublin, PolandDepartment of Family Medicine and Public Health, Faculty of Medicine, University of Opole, Opole, PolandDepartment of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, PolandDepartment of Nephrology, Hypertension and Family Medicine, Medical University of Lodz (MUL), Lodz, PolandDepartment of Endocrinology and Metabolic Diseases, Polish Mother’s Memorial Hospital Research Institute (PMMHRI), Lodz, PolandDepartment of Ophthalmology, University of Warmia and Mazury, Olsztyn, PolandCardiovascular diseases (CVD) prevention does not only mean effective fight against the existing and well-recognized cardiovascular risk factors, but also against their complications, including micro- and macrovascular complications. Only then we might comprehensively reduce CVD burden and cardiovascular and cause-specific morbidity and mortality. In relation to obesity, prediabetes and especially diabetes, we recognize a number of potential dangerous non-cardiovascular complications, such as neuropathy, nephropathy and retinopathy. The latter’s prevalence is even 30–40% and may appear in as many as 15% of patients with prediabetes. If not treated well it might result in the need for eye surgery or even vision loss. Fenofibrate has had a long history of evidence suggesting its preventive role in primary and especially secondary prevention of retinopathy, what has been investigated since the FIELD trial 19 years ago. Thus, given the obesity (the prevalence of 30% in Poland) and diabetes (10% which is predicted to be doubled in next 25 years) epidemic, we should look for the effective methods not only to optimize fasting blood glucose and haemoglobin A1C, but also atherogenic dyslipidaemia and their complications, including retinopathy. In this Position Paper by the Polish Lipid Association (PoLA) we have reviewed the current stage of knowledge on possible mechanisms by which fenofibrate may contribute to retinopathy prevention, available data on safety and efficacy, to finally recommend administering fenofibrate in prevention of this dangerous diabetic complication, which significantly affects quality of life and disability-adjusted life-years (DALY). This intervention – well-recognized and already in common use in diabetic patients – may significantly improve population health in Poland and worldwide.https://www.archivesofmedicalscience.com/The-prevention-opportunities-of-retinopathy-in-diabetic-patients-position-paper-endorsed,197331,0,2.htmlcomplicationsdiabetesfenofibratepreventionretinopathytherapy |
| spellingShingle | Maciej Banach Stanisław Surma Grzegorz Dzida Jacek Jóźwiak Bogusław Okopień Jacek Rysz Konrad Szosland Andrzej Grzybowski The prevention opportunities of retinopathy in diabetic patients – position paper endorsed by the Polish Lipid Association Archives of Medical Science complications diabetes fenofibrate prevention retinopathy therapy |
| title | The prevention opportunities of retinopathy in diabetic patients – position paper endorsed by the Polish Lipid Association |
| title_full | The prevention opportunities of retinopathy in diabetic patients – position paper endorsed by the Polish Lipid Association |
| title_fullStr | The prevention opportunities of retinopathy in diabetic patients – position paper endorsed by the Polish Lipid Association |
| title_full_unstemmed | The prevention opportunities of retinopathy in diabetic patients – position paper endorsed by the Polish Lipid Association |
| title_short | The prevention opportunities of retinopathy in diabetic patients – position paper endorsed by the Polish Lipid Association |
| title_sort | prevention opportunities of retinopathy in diabetic patients position paper endorsed by the polish lipid association |
| topic | complications diabetes fenofibrate prevention retinopathy therapy |
| url | https://www.archivesofmedicalscience.com/The-prevention-opportunities-of-retinopathy-in-diabetic-patients-position-paper-endorsed,197331,0,2.html |
| work_keys_str_mv | AT maciejbanach thepreventionopportunitiesofretinopathyindiabeticpatientspositionpaperendorsedbythepolishlipidassociation AT stanisławsurma thepreventionopportunitiesofretinopathyindiabeticpatientspositionpaperendorsedbythepolishlipidassociation AT grzegorzdzida thepreventionopportunitiesofretinopathyindiabeticpatientspositionpaperendorsedbythepolishlipidassociation AT jacekjozwiak thepreventionopportunitiesofretinopathyindiabeticpatientspositionpaperendorsedbythepolishlipidassociation AT bogusławokopien thepreventionopportunitiesofretinopathyindiabeticpatientspositionpaperendorsedbythepolishlipidassociation AT jacekrysz thepreventionopportunitiesofretinopathyindiabeticpatientspositionpaperendorsedbythepolishlipidassociation AT konradszosland thepreventionopportunitiesofretinopathyindiabeticpatientspositionpaperendorsedbythepolishlipidassociation AT andrzejgrzybowski thepreventionopportunitiesofretinopathyindiabeticpatientspositionpaperendorsedbythepolishlipidassociation AT maciejbanach preventionopportunitiesofretinopathyindiabeticpatientspositionpaperendorsedbythepolishlipidassociation AT stanisławsurma preventionopportunitiesofretinopathyindiabeticpatientspositionpaperendorsedbythepolishlipidassociation AT grzegorzdzida preventionopportunitiesofretinopathyindiabeticpatientspositionpaperendorsedbythepolishlipidassociation AT jacekjozwiak preventionopportunitiesofretinopathyindiabeticpatientspositionpaperendorsedbythepolishlipidassociation AT bogusławokopien preventionopportunitiesofretinopathyindiabeticpatientspositionpaperendorsedbythepolishlipidassociation AT jacekrysz preventionopportunitiesofretinopathyindiabeticpatientspositionpaperendorsedbythepolishlipidassociation AT konradszosland preventionopportunitiesofretinopathyindiabeticpatientspositionpaperendorsedbythepolishlipidassociation AT andrzejgrzybowski preventionopportunitiesofretinopathyindiabeticpatientspositionpaperendorsedbythepolishlipidassociation |